Gilead’s Trodelvy Fails to Meet Main Goal in Breast Cancer Study but Shows Early Survival Trend

Gilead’s Trodelvy did not significantly improve progression-free survival in a key late-stage study for common breast cancer, though early data hints at a possible survival benefit.